Scholarlink

Background <p>This study evaluated the predictive value of tumor-infiltrating lymphocytes (TILs) in residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC).</p> Patients and methods <p>Patients with TNBC treated between 2008 and 2019 who presented with residual disease after NAC were included. Tumor samples were assessed before and after treatment, with TILs quantified as the percentage of mononuclear inflammatory cells in the tumor stroma. TILs levels were analyzed as both continuous and categorical variables (high ≥ 30%, low &lt; 30%). Among the 60 patients evaluated, the mean age was 52.6 ± 1.2 years (range: 28–78 years), with most receiving standard NAC, consisting of anthracycline and cyclophosphamide followed by docetaxel.</p> Results <p> A significant increase in TILs levels post-NAC was observed, with 55% of tumors classified as high TILs, compared to 90% classified as low TILs before treatment (McNemar’s test, <i>p</i> ≤ 0.0001). However, post-NAC TILs increase was not statistically associated with disease-free survival or overall survival.</p> Conclusion <p>These findings suggest an immunologic modulation of the tumor microenvironment in residual TNBC, highlighting the potential role of identifying immune-enriched residual tumors as candidates for adjuvant strategies, including immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic relevance of increased tumor-infiltrating lymphocytes in residual TNBC following neoadjuvant chemotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月5日

查看全文
  • Nathalia Cruz da Costa,
  • Alexandra Cauduro Ponso Fernandes,
  • Andrea Pires Souto Damin

摘要

Background

This study evaluated the predictive value of tumor-infiltrating lymphocytes (TILs) in residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC).

Patients and methods

Patients with TNBC treated between 2008 and 2019 who presented with residual disease after NAC were included. Tumor samples were assessed before and after treatment, with TILs quantified as the percentage of mononuclear inflammatory cells in the tumor stroma. TILs levels were analyzed as both continuous and categorical variables (high ≥ 30%, low < 30%). Among the 60 patients evaluated, the mean age was 52.6 ± 1.2 years (range: 28–78 years), with most receiving standard NAC, consisting of anthracycline and cyclophosphamide followed by docetaxel.

Results

A significant increase in TILs levels post-NAC was observed, with 55% of tumors classified as high TILs, compared to 90% classified as low TILs before treatment (McNemar’s test, p ≤ 0.0001). However, post-NAC TILs increase was not statistically associated with disease-free survival or overall survival.

Conclusion

These findings suggest an immunologic modulation of the tumor microenvironment in residual TNBC, highlighting the potential role of identifying immune-enriched residual tumors as candidates for adjuvant strategies, including immunotherapy.